迈向哮喘急性发作的个体化治疗策略
本文综述指出哮喘急性发作定义不清、治疗仍以支气管扩张剂和全身糖皮质激素为主。文章梳理发作危险因素、风险干预策略及发作特征,提出以表型分型和个体化治疗为方向的改进路径,以减少反复激素暴露的不良影响。
要点
- 哮喘急性发作每年致英国超9万住院、近1500人死亡。
- 长期管理已按异质性表型和可治疗特征个体化,急性发作仍滞后。
- 需基于发作特征开展表型分型以推进个体化治疗。
核心结论
- 哮喘急性发作的定义与评估存在不足,当前治疗局限于支气管扩张剂和全身糖皮质激素。
- 应基于发作特征推进表型分型与个体化治疗,以减少反复激素暴露的不良反应。
研究设计与样本
- 综述,探讨哮喘急性发作在描述、评估和管理方面的现有局限。
主要发现
- 急性发作可造成显著直接与间接费用,并加速且永久性损害肺功能。
- 长期哮喘管理已转向异质性表型与可治疗特征理念,急性发作管理尚未同步。
关键数值与推荐
- 哮喘急性发作的现有治疗为支气管扩张剂和全身糖皮质激素。
临床怎么用
- 临床应重视识别发作危险因素并采取风险干预策略。
- 可尝试依据发作特征进行表型分型,为个体化治疗提供依据。
- 减少反复全身糖皮质激素疗程以降低相关不良反应。
局限性
- 哮喘急性发作目前定义不清、认识不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma attacks (exacerbations) are common, accounting for over 90 000 UK hospital admissions per annum. They kill nearly 1500 people per year in the UK, have significant associated direct and indirect costs and lead to accelerated and permanent loss of lung function. The recognition of asthma as a heterogeneous condition with multiple phenotypes has revolutionised the approach to the long-term management of the condition, with greater emphasis on personalised treatment and the introduction of the treatable traits concept. In contrast asthma attacks are poorly defined and understood and our treatment approach consists of bronchodilators and systemic corticosteroids. This review aims to explore the current limitations in the description, assessment and management of asthma attacks. We will outline the risk factors for attacks, strategies to modify this risk and describe the recognised characteristics of attacks as a first step towards the development of an approach for phenotyping and personalising the treatment of these critically important events. By doing this, we hope to gradually improve asthma attack treatment and reduce the adverse effects associated with recurrent courses of corticosteroids.
引用
- Martin MJ, Beasley R, Harrison TW, et al. Towards a personalised treatment approach for asthma attacks. Thorax. 2020. PMID: 32839286. doi:10.1136/thoraxjnl-2020-214692
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。